UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 84 filers reported holding UROGEN PHARMA LTD in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,010 | +35.4% | 1,000 | 0.0% | 0.00% | – |
Q2 2023 | $10,350 | +12.0% | 1,000 | 0.0% | 0.00% | – |
Q1 2023 | $9,240 | +4.2% | 1,000 | 0.0% | 0.00% | – |
Q4 2022 | $8,870 | +10.9% | 1,000 | 0.0% | 0.00% | – |
Q3 2022 | $8,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
Q2 2022 | $8,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
Q1 2022 | $8,000 | -11.1% | 1,000 | 0.0% | 0.00% | – |
Q4 2021 | $9,000 | -43.8% | 1,000 | 0.0% | 0.00% | – |
Q3 2021 | $16,000 | +6.7% | 1,000 | 0.0% | 0.00% | – |
Q2 2021 | $15,000 | -21.1% | 1,000 | 0.0% | 0.00% | – |
Q1 2021 | $19,000 | +5.6% | 1,000 | 0.0% | 0.00% | – |
Q4 2020 | $18,000 | -5.3% | 1,000 | 0.0% | 0.00% | – |
Q3 2020 | $19,000 | -26.9% | 1,000 | 0.0% | 0.00% | – |
Q2 2020 | $26,000 | +52.9% | 1,000 | 0.0% | 0.00% | – |
Q1 2020 | $17,000 | +6.2% | 1,000 | +100.0% | 0.00% | – |
Q4 2019 | $16,000 | +45.5% | 500 | 0.0% | 0.00% | – |
Q3 2019 | $11,000 | -35.3% | 500 | 0.0% | 0.00% | – |
Q2 2019 | $17,000 | – | 500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |